ONCOLife presents an exclusive interview with John Santini, CEO of Vergent Bioscience. In this session, we explore how ...

ONCOLife presents an exclusive interview with Dr. John Gribben, Professor at the Cancer Institute in London. In this session, ...

ONCOLife presents an exclusive interview with Lorna Warwick, CEO of Lymphoma Coalition. In this session, we explore the critical role of patient advocacy in improving access to CAR T-cell therapy — a ...

Rznomics has received FDA Orphan Drug Designation for RZ-001, a novel RNA-based RZ-001 therapy for Liver Cancer and Hepatocellular carcinoma.

Johnson & Johnson announced the acquisition of Ambrx Biopharma for $2 billion, aiming to boost its oncology pipeline with Ambrx's innovative antibody drug conjugates.

With FDA Fast Track designation, the new non-opioid pain medication SRP-001 shows promising Phase 1 trial results, offering a safer alternative for pain management.

ONCOLife presents an exclusive interview with Dr. Miguel-Angel Perales, Co-Chair of the CAR T Vision initiative, as he shares his expert insights on the major barriers preventing eligible patients ...

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

The Innovation-Implementation Divide What the Index underscores is not a failure of scientific progress, but rather the growing complexity of applying that progress in real-world clinical care. Three ...

We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the future of breast cancer screening and the role of artificial intelligence ...